EVOTEC COMPLETES OF WITH EVT 101
Evotec has announced the successful completion of the single ascending-dose component of the Phase I clinical study with EVT 101, a subtype-specific NMDA receptor antagonist for the treatment of Alzheimer's disease. The study, in 48 young healthy subjects of whom 36 received EVT 101, showed that EVT 101 was well-absorbed, achieving good exposure levels, was extremely well-tolerated with no significant adverse events, and had a good pharmacokinetic profile consistent with once or twice daily oral dosing.
This result is significant, given the unfavorable side-effect profile of non-selective NMDA antagonists. EVT 101 has now moved into the multiple ascending dose stage of the Phase I study in both young and elderly volunteers.